Patents by Inventor Ruben Laguens
Ruben Laguens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180296641Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium.Type: ApplicationFiled: April 5, 2018Publication date: October 18, 2018Applicants: Sterrenbeld Biotechnologie North America, Inc., Fundacion Universitaria Dr. Rene G. FavaloroInventors: Ruben Laguens, Marcelo L. Arguelles, Gustavo Vera Janavel, Jose Alberto Crottogini, Carlos Alberto Melo, Ricardo Horacio Pichel, Marcelo Eduardo Criscuolo
-
Publication number: 20170252405Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium.Type: ApplicationFiled: April 18, 2017Publication date: September 7, 2017Applicants: Sterrenbeld Biotechnologie North America, Inc., Fundacion Universitaria Dr. Rene G. FavaloroInventors: Ruben Laguens, Marcelo L. Arguelles, Gustavo Vera Janavel, Jose Alberto Crottogini, Carlos Alberto Melo, Ricardo Horacia Pichel, Marcelos Eduardo Criscuolo
-
Publication number: 20160346352Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotde) is administered into the myocardium.Type: ApplicationFiled: June 6, 2016Publication date: December 1, 2016Applicants: Sterrenbeld Biotechnologie North America, Inc., Fundacion Universitaria Dr. Rene G. FavaloroInventors: Ruben Laguens, Marcelo L. Arguelles, Gustavo Vera Janavel, Jose Alberto Crottogini, Carlos Alberto Melo, Ricardo Horacia Pichel, Marcelos Eduardo Criscuolo
-
Publication number: 20140341972Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotde) is administered into the myocardium.Type: ApplicationFiled: February 10, 2014Publication date: November 20, 2014Applicants: Fundacion Universitaria Dr. Rene G. Favaloro, Sterrenbeld Biotechnologie North America, Inc.Inventors: RUBÉN LAGUENS, MARCELO L. ARGUELLES, GUSTAVO VERA JANAVEL, JOSÉ ALBERTO CROTTOGINI, CARLOS ALBERTO MELO, RICARDO HORACIA PICHEL, MARCELOS EDUARDO CRISCUOLO
-
Publication number: 20090275645Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium.Type: ApplicationFiled: June 18, 2009Publication date: November 5, 2009Applicants: Sterrenbeld Biotechnologie North America, Inc., Fundacion Universitaria Dr. Rene G. FavaloroInventors: Rubén Laguens, Marcelo L. Arguelles, Gustavo Leónidas Vera Janavel, José Alberto Crottogini, Carlos Alberto Melo, Ricardo Horacio Pichel, Marcelo Eduardo Criscuolo
-
Patent number: 7563777Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium.Type: GrantFiled: November 17, 2003Date of Patent: July 21, 2009Assignees: Sterrenbeld Biotechnologie North America, Inc., Fundacion Universitaria Dr. Rene G. FavaloroInventors: Rubén Laguens, Marcelo L. Argüelles, Gustavo Leónidas Vera Janavel, José Alberto Crottogini, Carlos Alberto Melo, Ricardo Horacio Pichel, Marcelo Eduardo Criscuolo
-
Publication number: 20050020522Abstract: The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotde) is administered into the myocardium.Type: ApplicationFiled: November 17, 2003Publication date: January 27, 2005Applicants: Sterrenbeld Biotechnologie North America, Inc., Fundacion Universitaria Dr. Rene G. FavaloroInventors: Ruben Laguens, Marcelo Arguelles, Gustavo Leonidas Janavel, Jose Crottogini, Carlos Melo, Ricardo Pichel, Marcelo Criscuolo